Bioventus Inc.
For the period ended Mar 28, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 28, 2026 · Filed May 6, 2026
BVS$11.18+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Condensed Statements of Cash Flows for the
Consolidated Condensed Statements of Cash Flows
(Amounts in thousands)
| Three Months Ended | ||
|---|---|---|
| March 28, 2026 | March 29, 2025 | |
| Operating activities: | ||
| Net income (loss) | $3,946 | $(3,322) |
| Adjustments to reconcile net income (loss) to net cash from operating activities: | ||
| Depreciation and amortization | 11,205 | 11,865 |
| Provision for credit losses | 230 | 650 |
| Equity-based compensation | 3,264 | 2,414 |
| Deferred income taxes | 135 | 43 |
| Loss on disposals | — | 81 |
| Unrealized loss (gain) on foreign currency fluctuations | 54 | (242) |
| Other, net | 275 | 381 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 7,318 | 9,004 |
| Inventories | (2,648) | (1,881) |
| Accounts payable and accrued expenses | (15,367) | (39,104) |
| Other current and noncurrent assets and liabilities | 522 | 780 |
| Net cash from operating activities | 8,934 | (19,331) |
| Investing activities: | ||
| Purchase of property and equipment | (574) | (826) |
| Net cash from investing activities | (574) | (826) |
| Financing activities: | ||
| Proceeds from issuance of Class A common stock | 120 | 150 |
| Tax withholdings on equity-based compensation | (1,044) | — |
| Payment of contingent consideration | — | (9,000) |
| Borrowing on revolver | — | 15,000 |
| Payment on revolver | — | (5,000) |
| Payments on long-term debt | (22,000) | — |
| Other, net | (220) | (203) |
| Net cash from financing activities | (23,144) | 947 |
| Effect of exchange rate changes on cash | (608) | 430 |
| Net change in cash and cash equivalents | (15,392) | (18,780) |
| Cash and cash equivalents at the beginning of the period | 51,238 | 41,582 |
| Cash and cash equivalents at the end of the period | $35,846 | $22,802 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Accounts payable for purchase of property, plant and equipment | $534 | $140 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.